What is the recommended evaluation and treatment for a suspected retroviral infection (e.g., HIV)?

Evaluation and Treatment of Suspected Retroviral (HIV) Infection

For suspected HIV infection, immediately perform combined HIV antibody and antigen testing (with HIV RNA if acute infection suspected), and if positive, initiate antiretroviral therapy (ART) as soon as the patient is ready, regardless of CD4 count or symptoms. 1

Initial Diagnostic Evaluation

When evaluating for HIV infection, obtain:

• Combined HIV antibody and antigen testing as the primary screening test 1
• HIV RNA level if clinical signs suggest acute/primary HIV infection (e.g., acute retroviral syndrome with fever, lymphadenopathy, rash) 1, 2
• Baseline CD4 count and HIV viral load once diagnosis confirmed 3
• Resistance testing before initiating therapy 1
• Hepatitis B surface antigen and Hepatitis C antibody 1
• Serum creatinine for renal function assessment 1
• Sexually transmitted infection screening (gonorrhea, chlamydia, syphilis) by nucleic acid amplification test 1

Critical Pitfall

Do not delay HIV RNA testing when acute retroviral syndrome is suspected—antibody tests may be negative during the first 2-4 weeks of infection while viral replication is highest 2. The acute phase is characterized by rapid viral dissemination, immune activation, and elevated inflammatory markers (particularly IP-10 and IFNγ) 2.

Treatment Initiation

Antiretroviral therapy should be initiated in ALL adults with confirmed HIV infection, regardless of CD4 count or symptom status. 1, 4, 3

Recommended First-Line Regimens

The standard approach uses three active drugs: two nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent 1, 5:

Preferred NRTI backbone options:

• Tenofovir disoproxil fumarate/emtricitabine, OR
• Abacavir/lamivudine 1, 6

Preferred third agent (choose one):

• Integrase strand transfer inhibitors (preferred due to high efficacy and favorable safety profile) 1, 5:
  • Dolutegravir
  • Bictegravir
  • Raltegravir
• Boosted protease inhibitor (darunavir or atazanavir) 1
• Non-nucleoside reverse transcriptase inhibitor (efavirenz or rilpivirine) 1

Alternative approach for specific patients:

• Dual therapy with dolutegravir plus lamivudine (or emtricitabine) is acceptable 1, 6

Special Considerations for Acute Infection

Early ART initiation during acute retroviral syndrome mitigates the severe immune activation, CD4+ depletion, and elevated viral loads characteristic of this phase 2. Long-term outcomes are generally similar in treated individuals regardless of whether they experienced ARS, but early treatment prevents the negative immunologic impacts 2.

Monitoring During Treatment

Initial monitoring:

• HIV viral load and CD4 count at baseline, then 2-4 weeks after starting ART 3
• Goal: HIV RNA suppression below quantification limits (<50 copies/mL) 7

Ongoing monitoring:

• HIV viral load every 3-6 months once suppressed 3
• CD4 count can be monitored less frequently once consistently >300-500 cells/μL and virally suppressed 3
• Renal function monitoring based on regimen (more frequent with tenofovir) 1

Management of Treatment Failure

Virological failure is defined as HIV RNA >200 copies/mL 1

When failure occurs:

1. Confirm the elevated viral load with repeat testing 1
2. Perform resistance testing while patient remains on the failing regimen (or within 4 weeks of stopping) 1
3. Never add a single active agent to a failing regimen—this promotes further resistance 1
4. Switch promptly to a new regimen using current and past resistance test results 1

Specific failure scenarios:

• NNRTI failure: Switch to dolutegravir plus 2 NRTIs (with ≥1 active drug by genotypic testing) 1
• Integrase inhibitor failure: Switch to boosted PI plus 2 NRTIs (with ≥1 active NRTI) 1
• Raltegravir/elvitegravir resistance: Use dolutegravir dosed twice daily plus ≥1 fully active agent 1
• Multiclass (3-class) resistance: Construct regimen using new drug classes (fostemsavir or ibalizumab) with ≥1 additional active drug 1

Important Caveat

PI failure due to resistance mutations is rare—failure usually reflects adherence issues rather than resistance 1. Address adherence barriers or switch to a more tolerable regimen rather than assuming resistance 1.

Drug Interactions and Comorbidities

Review all co-medications carefully, especially when using boosted protease inhibitors or when tenofovir alafenamide is part of the regimen, as dosing adjustments may be needed 1, 4. Consider renal function, bone health, cardiovascular risk, and hepatitis B co-infection when selecting regimens 1, 6, 3.

For patients with chronic hepatitis B, ensure the regimen includes agents active against HBV (tenofovir or emtricitabine/lamivudine); switching away from these without alternative HBV therapy risks HBV reactivation 1.